Homepage > Company > Media > Pharma News > 2017 > M&As this week: Egyptian American Enterprise Fund, Valeant Pharmaceuticals International

M&As this week: Egyptian American Enterprise Fund, Valeant Pharmaceuticals International

US-based private equity firm Egyptian American Enterprise Fund (EAEF) has acquired 46.5% stake in Egyptian ophthalmic pharmaceutical products developer Orchidia Pharmaceutical Industries for EGP700m ($39.59m).

EAEF has acquired 38% stake from SPE Capital (formerly Swicorp Private Equity), 3% from Orchidia Ossama Abbass and the rest through a capital increase.

US-based pharmaceutical company Valeant Pharmaceuticals International plans to divest its stake in female sexual health products developer Sprout Pharmaceuticals.

The divestment will enable the company to streamline its business operations.

10 November 2017

http://www.pharmaceutical-technology.com/

Read also

Mayo Clinic cancer expert highlights advancements in treating multiple myeloma

March is Myeloma Awareness Month, and Sikander Ailawadhi, M.D., hematologist/oncologist at Mayo Clinic Comprehensive Cancer Center, shares details about new advancements in research leading to bet...

Paxlovid Gets Advisory Panel Support for Full FDA Approval

The FDA’S Antimicrobial Drugs Advisory Committee (ADAC) voted 16 to 1 on Thursday in favorof Pfizer’s antiviral Paxlovid (nirmatrelvir and ritonavir) for the treatment of mild-to-moderate COVI...

FDA Approves Novartis Treatment Combination for Pediatric Glioma

The FDA has granted expanded approval to Novartis’ Tafinlar (dabrafenib) in combination with Novartis’ Mekinist (trametinib) for pediatric patients one year and older with low-grade glioma with...

FDA Offers Advice on NDAs for Postoperative Local Anesthetics

Sponsors developing long-acting local postoperative anesthetics should consider including novel, clinically meaningful endpoints in their trial design, the FDA has said in new draft guidance. ...